| Prefix | Name/Text |
| 1 | Service organisation |
| 1a. | prehospital |
| 1b. | hospital |
| 1c. | community |
| 1d. | new initiatives and developments |
| 2 | Ischemic stroke |
| 2a. | acute management – thrombolysis |
| 2b. | acute management – endovascular |
| 2c. | acute management – diagnosis/imaging |
| 2d. | acute management – neuroprotection |
| 2e. | acute management other |
| 3 | Haemorrhagic stroke |
| 3a. | acute management – treatment |
| 3b. | acute management – diagnosis/imaging |
| 3c. | acute management – other |
| 4 | Primary and secondary prevention |
| 4a. | ischaemic |
| 4b. | haemorrhagic |
| 4c. | other, eg small vessel disease |
| 5 | Stroke aetiology |
| 5a. | atherosclerosis |
| 5b. | small vessel disease |
| 5c. | heart brain |
| 5d. | other |
| 6 | Long-term consequences |
| 6a. | vascular cognitive impairment |
| 6b. | small vessel disease |
| 6c. | neuropsychiatric |
| 6d. | functional |
| 6e. | other |
| 7 | Rehabilitation |
| 8 | Stroke across people and populations |
| 8a. | epidemiology |
| 8b. | low & middle income settings |
| 8c. | sex differences |
| 8d. | ethnic or regional/cultural differences |
| 8e. | socioeconomic differences |
| 9 | Discovery science |
| 9a. | preclinical |
| 9b. | pathology |
| 9c. | fluid, imaging or digital biomarkers |
| 9d. | drug discovery |
| 9e. | OMICS (Genomics, proteomics, lipidomics and metabologmics) |
| 10 | Technologies |
| 10a. | devices |
| 10b. | imaging |
| 10c. | robotics |
| 10d. | artificial intelligence |
| 11 | Innovations in clinical research |
| 11a. | clinical trial design |
| 11b. | use of disease registries |
| 11c. | use of ‘big data’ |
| 11d. | use of biomarkers for patient selection |
| 11e. | other |
| 12 | Other |
Contact
Should you have any questions, please feel free to contact the Conference Secretariat in Basel, Switzerland:
Phone: +41 61 686 77 77
E-mail: abstracts@congrex.com
